Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Exagen (XGN) Cost of Revenue (2018 - 2025)

Historic Cost of Revenue for Exagen (XGN) over the last 8 years, with Q3 2025 value amounting to $7.2 million.

  • Exagen's Cost of Revenue rose 2973.22% to $7.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.5 million, marking a year-over-year increase of 1113.58%. This contributed to the annual value of $22.5 million for FY2024, which is 243.81% down from last year.
  • Per Exagen's latest filing, its Cost of Revenue stood at $7.2 million for Q3 2025, which was up 2973.22% from $6.8 million recorded in Q2 2025.
  • Exagen's Cost of Revenue's 5-year high stood at $7.2 million during Q3 2025, with a 5-year trough of $4.7 million in Q1 2021.
  • In the last 5 years, Exagen's Cost of Revenue had a median value of $5.8 million in 2022 and averaged $5.8 million.
  • As far as peak fluctuations go, Exagen's Cost of Revenue surged by 6330.14% in 2021, and later tumbled by 1092.09% in 2023.
  • Over the past 5 years, Exagen's Cost of Revenue (Quarter) stood at $4.9 million in 2021, then rose by 27.74% to $6.3 million in 2022, then fell by 10.92% to $5.6 million in 2023, then dropped by 7.86% to $5.2 million in 2024, then soared by 38.45% to $7.2 million in 2025.
  • Its last three reported values are $7.2 million in Q3 2025, $6.8 million for Q2 2025, and $6.4 million during Q1 2025.